RareCan, the UK’s only health tech company that specialises in supporting people with rare cancers, has been selected to join the prestigious KQ Labs programme
Knowing Paul’s cancer was fairly rare with little research into it made me feel frustrated and angry. He wanted to help find a cure and
The members of the RareCan community remain at the very heart of all we do Listen to Piers give an update on what it means
18th August 2022 – Rare Cancer in the News Professor Andy Hall looks at some recent news about the impact PARP inhibitors could have on
On Saturday 2nd July Sasha, will be taking a break from his current world tour to play a sell-out gig at the Gazelle Hotel in
Hexham, UK, 21 June 2022: RareCan, a direct-to-patient clinical trial recruitment platform bringing together the power of patients and their data to reduce the costs
During the Pandemic, I was diagnosed with a very rare and aggressive type of soft tissue cancer called angiosarcoma which was most likely caused by
In March 2022, Andy had the opportunity to present at the GIST Cancer UK annual patient and carer meeting and lead a discussion on ‘Patient
In December 2020, Kathy was diagnosed with Stage 3 Vaginal Cancer, which is exceedingly rare. I was not shocked about the cancer diagnosis as I
With our first research project underway in partnership with Teeside, Newcastle and Cambridge Universities our CEO, Piers Kotting, gives a brief insight into progress so far.
RareCan Limited is a company registered in England, number 12844377. Registered office address: 8 Park Avenue, Hexham, England, NE46 3EN. 0191 249 8555
